CA3242318A1 - Compositions and methods for targeted delivery to cells - Google Patents

Compositions and methods for targeted delivery to cells

Info

Publication number
CA3242318A1
CA3242318A1 CA3242318A CA3242318A CA3242318A1 CA 3242318 A1 CA3242318 A1 CA 3242318A1 CA 3242318 A CA3242318 A CA 3242318A CA 3242318 A CA3242318 A CA 3242318A CA 3242318 A1 CA3242318 A1 CA 3242318A1
Authority
CA
Canada
Prior art keywords
compositions
methods
targeted cell
cell administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242318A
Other languages
English (en)
French (fr)
Inventor
Daniel J. SIEGWART
Qiang Cheng
Sean Dilliard
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3242318A1 publication Critical patent/CA3242318A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3242318A 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells Pending CA3242318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163294066P 2021-12-27 2021-12-27
US63/294,066 2021-12-27
PCT/US2022/082411 WO2023129915A2 (en) 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells

Publications (1)

Publication Number Publication Date
CA3242318A1 true CA3242318A1 (en) 2023-07-06

Family

ID=87000245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242318A Pending CA3242318A1 (en) 2021-12-27 2022-12-27 Compositions and methods for targeted delivery to cells

Country Status (7)

Country Link
EP (1) EP4456921A2 (https=)
JP (1) JP2025500547A (https=)
CN (1) CN118660721A (https=)
AU (1) AU2022425201A1 (https=)
CA (1) CA3242318A1 (https=)
IL (1) IL313876A (https=)
WO (1) WO2023129915A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001254B (zh) * 2024-04-09 2024-07-26 北京悦康科创医药科技股份有限公司 靶向抗原呈递细胞的脂质组合物及其应用
WO2026062291A1 (en) 2024-09-23 2026-03-26 Aldexchem Kft. Silicon-containing spleen-targeted lnp delivery systems
KR20260043575A (ko) * 2024-09-24 2026-03-31 주식회사 녹십자 선택적 장기 표적 지질을 포함하는 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CA3103528A1 (en) * 2018-06-19 2019-12-26 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
WO2020051223A1 (en) * 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids

Also Published As

Publication number Publication date
JP2025500547A (ja) 2025-01-09
CN118660721A (zh) 2024-09-17
WO2023129915A3 (en) 2023-08-10
WO2023129915A2 (en) 2023-07-06
EP4456921A2 (en) 2024-11-06
IL313876A (en) 2024-08-01
AU2022425201A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
CA3242318A1 (en) Compositions and methods for targeted delivery to cells
MA47331A (fr) Compositions et procédés pour la déplétion des cellules cd137+
EP3370741A4 (en) METHOD AND COMPOSITIONS FOR GENETIZING BLOOD-GENERATING STEM CELLS
JOP20210043A1 (ar) تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3717022A4 (en) COMPOSITIONS AND METHODS OF DEPLOYMENT FROM CD5 + CELLS
EP2696678A4 (en) MEDIUM FOR IMPROVED ADMINISTRATION OF NUCLEIC ACIDS IN EUKARYOTIC CELLS
MX2013008902A (es) Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
MA45408A (fr) Compositions et procédés pour la déplétion des cellules cd117+
UA111770C2 (uk) Інгібітори бромдомену
EP3897748A4 (en) COMPOSITIONS AND METHODS FOR REPROGRAMMING DISEASE MUSCLE SKELETAL CELLS
IN2014KN00769A (https=)
EP1757306A4 (en) MEDIUM FOR INDUCING CARCINOMA CELL SPECIFIC APOPTOSIS WITH A GENE AS A TARGET; Which is relevant for chromosome stabilization
EA201592103A3 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
MX2016000038A (es) Amidas de piperidina fusionadas como moduladores de canales de iones.
CR11629A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA- DESATURASA.
EP4255502A4 (en) COMPOSITIONS AND METHODS FOR TARGETING BCL11A
EP3417061A4 (en) METHOD AND COMPOSITIONS FOR GENETIZING STEM CELLS
EP3774890A4 (en) METHODS AND COMPOSITIONS FOR THE TARGETING OF C-TYPE LECTIN FROM SINUSOIDAL ENDOTHELIAL CELLS OF THE LIVER AND LYMPH NODES (LSECTIN)
EP3347449A4 (en) ZELLEX PANSION PROCEDURE AND THERAPEUTIC COMPOSITIONS
PE20150709A1 (es) Benzamidas
EP3307284A4 (en) COMPOSITIONS AND METHOD FOR ENRICHMENT OF CELLS
EP3969587A4 (en) COMPOSITIONS AND METHODS OF CHIMERIC ACETYLCHOLINE RECEPTOR-AUTOANTIBODY RECEPTOR CELLS
EP3801577A4 (en) METHOD AND COMPOSITIONS USING TANKYRASE INHIBITOR FOR GENERATING INSULIN-PRODUCING CELLS
EP4352239A4 (en) Methods and compositions for generating mitochondria replaced lymphoid cells
EP4422639A4 (en) ENPP1 INHIBITORS AS METASTASIS INHIBITORS

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240702

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250411

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209